Arnold C. Hanish - 30 Dec 2025 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Reporting relationship
Director
Issuer ticker
SLRX
Reported as of
30 Dec 2025
Net transaction value
-$17.27
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
02 Jan 2026, 17:13:54 UTC
Prior SEC filing
24 Nov 2025
Next SEC filing
22 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/Mark Rosenblum, as Attorney-in-Fact

Key filing fact

Arnold C. Hanish filed Form 4 for Salarius Pharmaceuticals, Inc. (SLRX) on 02 Jan 2026.

Key facts

  • This page summarizes Arnold C. Hanish's Form 4 filing for Salarius Pharmaceuticals, Inc. (SLRX).
  • 2 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 02 Jan 2026, 17:13.

Change

  • Previous filing in this sequence was filed on 24 Nov 2025.
  • Current net transaction value: -$17.27.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001233253 Primary reporting owner

HANISH ARNOLD C

Relationship
Director
Address
C/O SALARIUS PHARMACEUTICALS, INC., 2450 HOLCOMBE BLVD., SUITE X, HOUSTON
Signature
/s/Mark Rosenblum, as Attorney-in-Fact
Signature date
02 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SLRX transaction

Common Stock

Sale

Transaction value
$9.6
Shares
-15
Change %
-0.3%
Price
$0.6397
Shares after
5,000
Date
30 Dec 2025
Ownership
By Arnold C. Hanish Trust
SLRX transaction

Common Stock

Sale

Transaction value
$7.68
Shares
-12
Change %
-100%
Price
$0.6397
Shares after
0
Date
30 Dec 2025
Ownership
Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .